The conversion stage of skin carcinogenesis.

F. Marks,G. Fürstenberger

DOI: https://doi.org/10.1093/CARCIN/11.12.2085

1990-12-01

Carcinogenesis

Abstract:Cet article tente de rassembler toutes les donnees recentes sur l'etape de conversion au phase I de la promotion de la carcinogenese de la peau en se basant sur des preuves experimentales afin de donner une definition de ce nouveau concept

What problem does this paper attempt to address?

Integrative Pharmacogenomics Analysis of Patient-Derived Xenografts

Arvind Singh Mer,Wail Ba-alawi,Petr Smirnov,Yi Xiao Wang,Ben Brew,Janosch Ortmann,Ming-Sound Tsao,David Cescon,Anna Goldenberg,Benjamin Haibe-Kains

DOI: https://doi.org/10.1101/471227

IF: 11.2

2019-01-01

Cancer Research

Abstract:AbstractIdentifying robust biomarkers of drug response constitutes a key challenge in precision medicine. Patient-derived tumor xenografts (PDX) have emerged as reliable preclinical models that more accurately recapitulate tumor response to chemo- and targeted therapies. However, the lack of computational tools makes it difficult to analyze high-throughput molecular and pharmacologic profiles of PDX. We have developed Xenograft Visualization & Analysis (Xeva), an open-source software package for in vivo pharmacogenomic datasets that allows for quantification of variability in gene expression and pathway activity across PDX passages. We found that only a few genes and pathways exhibited passage-specific alterations and were therefore not suitable for biomarker discovery. Using the largest PDX pharmacogenomic dataset to date, we identified 87 pathways that are significantly associated with response to 51 drugs (FDR < 0.05). We found novel biomarkers based on gene expressions, copy number aberrations, and mutations predictive of drug response (concordance index > 0.60; FDR < 0.05). Our study demonstrates that Xeva provides a flexible platform for integrative analysis of preclinical in vivo pharmacogenomics data to identify biomarkers predictive of drug response, representing a major step forward in precision oncology.Significance:A computational platform for PDX data analysis reveals consistent gene and pathway activity across passages and confirms drug response prediction biomarkers in PDX.See related commentary by Meehan, p. 4324
Proteomics and personalized patient-derived xenograft models identify treatment opportunities for a progressive malignancy within a clinically actionable timeframe and change care

Georgina D. Barnabas,Tariq A. Bhat,Verena Goebeler,Pascal Leclair,Nadine Azzam,Nicole Melong,Colleen Anderson,Alexis Gom,Seohee An,Enes K. Ergin,Yaoqing Shen,Andy J. Mungall,Karen L. Mungall,Christopher A. Maxwell,Gregor S.D. Reid,Martin Hirst,Steven Jones,Jennifer A. Chan,Donna L. Senger,Jason N. Berman,Seth J. Parker,Jonathan W. Bush,Caron Strahlendorf,Rebecca J. Deyell,Chinten J. Lim,Philipp F. Lange,PROFYLE Program

DOI: https://doi.org/10.1101/2024.07.04.24309923

2024-07-08

Abstract:Increased access to high-throughput DNA sequencing platforms has transformed the diagnostic landscape of pediatric malignancies by identifying and integrating actionable genomic or transcriptional features that refine diagnosis, classification, and treatment. Yet less than 10% of treated patients show a positive response and translating precision oncology data into feasible and effective therapies for hard-to-cure childhood, adolescent, and young adult malignancies remains a significant challenge. Combining the identification of therapeutic targets at the protein and pathway levels with demonstration of treatment response in personalized models holds great promise. Here we present the case for combining proteomics with patient-derived xenograft (PDX) models to identify personalized treatment options that were not apparent at genomic and transcriptomic levels. Proteome analysis with immunohistochemistry (IHC) validation of formalin-fixed paraffin-embedded sections from an adolescent with primary and metastatic spindle epithelial tumor with thymus-like elements (SETTLE) was completed within two weeks of biopsy. The results identified an elevated protein level of SHMT2 as a possible target for therapy with the commercially available anti-depressant sertraline. Within 2 months and ahead of a molecular tumor board, we confirmed a positive drug response in a personalized chick chorioallantoic membrane (CAM) model of the SETTLE tumor (CAM-PDX). Following the failure of cytotoxic chemotherapy and second-line therapy, a treatment of sertraline was initiated for the patient. After 3 months of sertraline treatment the patient showed decreased tumor growth rates, albeit with clinically progressive disease. Significance: Overall, we demonstrate that proteomics and fast-track personalized xenograft models can provide supportive pre-clinical data in a clinically meaningful timeframe to support medical decision-making and impact the clinical practice. By this we show that proteome-guided and functional precision oncology are feasible and valuable complements to the current genome- driven precision oncology practices.

Oncology
Proteogenomic Integration Reveals Therapeutic Targets in Breast Cancer Xenografts.

Kuan-lin Huang,Shunqiang Li,Philipp Mertins,Song Cao,Harsha P. Gunawardena,Kelly V. Ruggles,D. R. Mani,Karl R. Clauser,Maki Tanioka,Jerry Usary,Shyam M. Kavuri,Ling Xie,Christopher Yoon,Jana W Qiao,John Wrobel,Matthew A. Wyczalkowski,Petra Erdmann-Gilmore,Jacqueline E. Snider,Jeremy Hoog,Purba Singh,Beifang Niu,Zhanfang Guo,Sam Qiancheng Sun,Souzan Sanati,Emily Kawaler,Xuya Wang,Adam Scott,Kai Ye,Michael D. McLellan,Michael C. Wendl,Anna Malovannaya,Jason M. Held,Michael A. Gillette,David Fenyö,Christopher R. Kinsinger,Mehdi Mesri,Henry Rodriguez,Sherri R. Davies,Charles M. Perou,Cynthia Ma,R. Reid Townsend,Xian Chen,Steven A. Carr,Matthew J. Ellis,Li Ding

DOI: https://doi.org/10.1038/ncomms14864

2017-01-01

Abstract:Recent advances in mass spectrometry (MS) have enabled extensive analysis of cancer proteomes. Here, we employed quantitative proteomics to profile protein expression across 24 breast cancer patient-derived xenograft (PDX) models. Integrated proteogenomic analysis shows positive correlation between expression measurements from transcriptomic and proteomic analyses; further, gene expression-based intrinsic subtypes are largely re-capitulated using non-stromal protein markers. Proteogenomic analysis also validates a number of predicted genomic targets in multiple receptor tyrosine kinases. However, several protein/phosphoprotein events such as overexpression of AKT proteins and ARAF, BRAF, HSP90AB1 phosphosites are not readily explainable by genomic analysis, suggesting that druggable translational and/or post-translational regulatory events may be uniquely diagnosed by MS. Drug treatment experiments targeting HER2 and components of the PI3K pathway supported proteogenomic response predictions in seven xenograft models. Our study demonstrates that MS-based proteomics can identify therapeutic targets and highlights the potential of PDX drug response evaluation to annotate MS-based pathway activities.
Proteomics‐based interrogation of the kinome and its implications for precision oncology

Terry C. C. Lim Kam Sian,Anderly C. Chüeh,Roger J. Daly

DOI: https://doi.org/10.1002/pmic.202000161

2021-03-08

PROTEOMICS

Abstract:The identification of specific protein kinases as oncogenic drivers in a variety of cancer types, coupled with the clinical success of particular kinase‐directed targeted therapies, has cemented the human kinome as an attractive source of 'actionable' targets for cancer therapy. However, 'mining' of the human kinome for precision oncology applications has yet to yield its full potential. This reflects a variety of issues, including oncogenic kinase dysregulation at levels not detectable by genomic sequencing and the uncharacterized nature of a considerable fraction of the kinome. In addition, selective therapeutic targeting of specific kinases requires efficient mapping of total kinome space impacted by candidate small molecule drugs. Fortunately, recent developments in proteomics techniques, particularly in mass spectrometry‐based phosphoproteomics and kinomics, provide the necessary technology platforms to address these impediments. Moreover, initiatives such as the Clinical Proteomic Tumour Analysis Consortium have enabled the generation, deposition and integration of genomic, transcriptomic and (phospho)proteomic data for many cancer types, providing unprecedented insights into oncogenic kinases and cancer cell signalling generally. These multi‐omic data are identifying novel therapeutic targets, highlighting opportunities for drug re‐purposing, and helping assign optimal therapies to specific tumour subtypes, heralding a new era of 'enhanced' precision oncology.This article is protected by copyright. All rights reserved

biochemistry & molecular biology,biochemical research methods
Personalized Cancer Therapy Using a Patient-Derived Tumor Tissue Xenograft Model: a Translational Field Worthy of Exploring Further?

Ketao Jin,Kuifeng He,Guangliang Li,Lisong Teng

DOI: https://doi.org/10.2217/pme.10.48

2010-01-01

Personalized Medicine

Abstract:It has long been observed that interpatient variability in response to anticancer drugs is associated with different outcomes. Oncologists continually hold the desire of matching the right therapeutic regimen with the right cancer patient, which is termed 'personalized cancer therapy'. Rapid advances in genetics, genomics and related technologies are promising a new era of personalized cancer therapy based on individual molecular biomarkers. However, these molecular predictors of tumor response are far from perfect. Because of the inherent limitations in the current approaches for anticancer drugs response prediction, the need for new techniques to predict tumor response to therapy is urgent. Using a patient-derived human tumor tissue (PDTT) xenograft model to predict tumor response to therapy might be an ideal candidate method to choose. This article provides an overview of the achievements and limitations of genetic, genomic and proteomic molecular markers for personalized cancer therapy, and further discusses the potentials of using a PDTT xenograft model as a candidate strategy for personalized cancer therapy.
Proteomic insights into paediatric cancer: Unravelling molecular signatures and therapeutic opportunities

Bhavna D Padhye,Urwah Nawaz,Peter G Hains,Roger R Reddel,Phillip J Robinson,Qing Zhong,Rebecca C Poulos

DOI: https://doi.org/10.1002/pbc.30980

Abstract:Survival rates in some paediatric cancers have improved greatly over recent decades, in part due to the identification of diagnostic, prognostic and predictive molecular signatures, and the development of risk-directed therapies. However, other paediatric cancers have proved difficult to treat, and there is an urgent need to identify novel biomarkers that reveal therapeutic opportunities. The proteome is the total set of expressed proteins present in a cell or tissue at a point in time, and is vastly more dynamic than the genome. Proteomics holds significant promise for cancer research, as proteins are ultimately responsible for cellular phenotype and are the target of most anticancer drugs. Here, we review the discoveries, opportunities and challenges of proteomic analyses in paediatric cancer, with a focus on mass spectrometry (MS)-based approaches. Accelerating incorporation of proteomics into paediatric precision medicine has the potential to improve survival and quality of life for children with cancer.
A Targeted Quantitative Proteomics Strategy for Global Kinome Profiling of Cancer Cells and Tissues

Yongsheng Xiao,Lei Guo,Yinsheng Wang

DOI: https://doi.org/10.1074/mcp.M113.036905

IF: 7.381

2014-01-01

Molecular & Cellular Proteomics

Abstract:Kinases are among the most intensively pursued enzyme superfamilies as targets for anti-cancer drugs. Large data sets on inhibitor potency and selectivity for more than 400 human kinases became available recently, offering the opportunity to design rationally novel kinase-based anti-cancer therapies. However, the expression levels and activities of kinases are highly heterogeneous among different types of cancer and even among different stages of the same cancer. The lack of effective strategy for profiling the global kinome hampers the development of kinase-targeted cancer chemotherapy. Here, we introduced a novel global kinome profiling method, based on our recently developed isotope-coded ATP-affinity probe and a targeted proteomic method using multiple-reaction monitoring (MRM), for assessing simultaneously the expression of more than 300 kinases in human cells and tissues. This MRM-based assay displayed much better sensitivity, reproducibility, and accuracy than the discovery-based shotgun proteomic method. Approximately 250 kinases could be routinely detected in the lysate of a single cell line. Additionally, the incorporation of iRT into MRM kinome library rendered our MRM kinome assay easily transferrable across different instrument platforms and laboratories. We further employed this approach for profiling kinase expression in two melanoma cell lines, which revealed substantial kinome reprogramming during cancer progression and demonstrated an excellent correlation between the anti-proliferative effects of kinase inhibitors and the expression levels of their target kinases. Therefore, this facile and accurate kinome profiling assay, together with the kinome-inhibitor interaction map, could provide invaluable knowledge to predict the effectiveness of kinase inhibitor drugs and offer the opportunity for individualized cancer chemotherapy.
Abstract 937: Prioritizing treatment targets for an adolescent with metastatic processive malignancy using proteomics and personalized xenograft models within an actionable timeframe

Georgina D. Barnabas,Tariq A. Bhat,Verena Goebeler,Pascal Leclair,Nadine Azzam,Nicole Melong,Jason N. Berman,Jennifer A. Chan,Donna L. Senger,Seth Parker,Christopher A. Maxwell,Gregor S. Reid,Jonathan Bush,Caron Strahlendorf,Rebecca Deyell,C James Lim,Philipp F. Lange

DOI: https://doi.org/10.1158/1538-7445.am2024-937

IF: 11.2

2024-03-31

Cancer Research

Abstract:Translation of precision oncology data into feasible precision therapies for hard-to-cure childhood, adolescent and young adult malignancies remains a significant challenge. Identifying therapeutic targets at the protein and pathway level and demonstrating treatment response in personalized models hold great promise, particularly for combination therapies, but may be considered complex and time consuming. Here, we present the case of an adolescent with metastatic, progressive spindle epithelial tumor with thymus-like differentiation (SETTLE) and evaluate how proteomics combined with rapid patient-derived models can identify treatment options not apparent at the genome or transcript level. Mass spectrometric proteome analysis of macro-dissected tumor and adjacent normal from formalin fixed paraffin embedded sections was completed within two weeks of biopsy and identified key proteins involved in one-carbon metabolism, including SHMT2 and DHFR as possible targets for single or combination therapy. Elevated SHMT2 levels were validated by immunohistochemistry and compared to levels across AYA tumors. Based on the suitability for an innovative therapy trial, we prioritized single-agent sertraline, a commercially available anti-depressant medication that inhibits SHMT2, and confirmed a positive drug response in both chicken chorioallantoic membrane (CAM) and larval zebrafish xenografts generated from the patient. Retrospective expansion in a murine xenograft enabled metabolic tracing on isolated SETTLE- patient-derived xenograft cells using 13C6-glucose confirming SHMT2 activity and response to in vitro treatment. Following failure of cytotoxic chemotherapy and second-line sorafenib treatment, a monotherapy trial of sertraline was initiated by the patient but stopped after 8 weeks after evidence of progressive disease. Possible combination therapies were evaluated further in the patient-derived models. Combining sertraline with the common antibiotic trimethoprim, resulted in enhanced growth inhibition of SETTLE cells in the larval zebrafish xenografts. Significance: Overall, we demonstrate that proteomics and personalized xenograft models may provide supportive pre-clinical data in a clinically meaningful timeframe to support medical decision-making and impact clinical practice. Citation Format: Georgina D. Barnabas, Tariq A. Bhat, Verena Goebeler, Pascal Leclair, Nadine Azzam, Nicole Melong, Jason N. Berman, Jennifer A. Chan, Donna L. Senger, Seth Parker, Christopher A. Maxwell, Gregor S. Reid, Jonathan Bush, Caron Strahlendorf, Rebecca Deyell, C James Lim, Philipp F. Lange. Prioritizing treatment targets for an adolescent with metastatic processive malignancy using proteomics and personalized xenograft models within an actionable timeframe [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 937.

oncology
Abstract 6915: Integrated proteogenomic analysis for the NCI patient-derived cancer model repository

Peter I. Wu,Li Chen,Yuri Kotliarov,Jianwen Fang,Yingdong Zhao,Yvonne Evrard,Lijun Chen,Shahanawaz Jiwani,Biswajit Das,Chris A. Karlovich,Hui Zhang,Lisa McShane,Melinda G. Hollingshead,Mickey Williams,James H. Doroshow

DOI: https://doi.org/10.1158/1538-7445.am2024-6915

IF: 11.2

2024-03-23

Cancer Research

Abstract:Background: Studying protein expression involved in cancer from patient-derived xenografts (PDX) enhances understanding of tumorigenesis and may shed light on patient therapeutic decisions. Recently, mass spectrometry-based proteomics sequencing techniques have enabled the acquisition of high-throughput PDX protein/phosphoprotein expression profiles and paved a way for investigating oncogenic signaling pathways and their interactions in different tumor histologies. Integrated analysis of these proteomic data with existing biomarkers derived from whole exome and RNAseq data will provide the community with a rich resource for translational research. Materials and methods: iTRAQ-based proteomics/phospho-proteomics data, with 11 Tandem Mass Tag (TMT) channels, were processed and median-normalized at gene level. The gene expression data were derived from tximport and DESeq2 from of RNA-Seq. In addition, whole exome sequencing (WES) data were used to compute mutations and copy number profiles. For data visualization, the R Bioconductor package ComplexHeatmap was used extensively. Results: PDX proteomics/phospho-proteomics data were analyzed alongside with gene expression, copy number and mutational profiles for several cancer types, revealing vivid molecular regulation for many cancer-related pathways. A moderate yet significant Spearman correlation coefficient of over 0.45 and 0.5 was observed between proteomics and RNA-Seq data at gene and pathway level, respectively. The PDX protein and gene expression pattern from common cancer regulatory pathways of bladder (BLCA, n=32 models), colon (COAD, n=82), lung (NSCLC, n=32), pancreatic (PAAD, n=52), metastatic breast cancer (CSNOS) (n=16) and other histologies were aggregated and discussed at the model level. EGFR, MET and cell-cycle genes CDKN2A and CDKN2B exhibited significant positive correlation among copy number, gene expression and protein expression profiles. Protein and gene expression profiles of PAM50 genes were shown for CSNOS samples, to further sub-classify or correct misclassification. Further analysis using proteomics/phospho-proteomics data with CNA identified several trans-regulatory events. Lastly, we identified RTN1 as a potential biomarker, exhibiting lower expression in sensitive rare-tumor PDX models prior to Axitinib and Vandetanib treatment. Conclusions: With the multi-omics datasets comprising proteomics/phospho-proteomics, RNA-Seq and WES datasets from the NCI Patient Derived Models Repository cohort, we were able to query some important cancer biological processes at a higher resolution. In addition, we revealed gene- and pathway-level regulatory differences from various histologies. Overall, the multi-omics data from PDX models showed promising recapitulation of original tumor activity and should continue to serve as an amenable and scalable drug screening platform for pre-clinical trials. Citation Format: Peter I. Wu, Li Chen, Yuri Kotliarov, Jianwen Fang, Yingdong Zhao, Yvonne Evrard, Lijun Chen, Shahanawaz Jiwani, Biswajit Das, Chris A. Karlovich, Hui Zhang, Lisa McShane, Melinda G. Hollingshead, Mickey Williams, James H. Doroshow. Integrated proteogenomic analysis for the NCI patient-derived cancer model repository [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 6915.

oncology
Proteomics for cancer drug design

Amanda Haymond,Justin B. Davis,Virginia Espina

DOI: https://doi.org/10.1080/14789450.2019.1650025

2019-08-03

Expert Review of Proteomics

Abstract:Introduction: Signal transduction cascades drive cellular proliferation, apoptosis, immune, and survival pathways. Proteins have emerged as actionable drug targets because they are often dysregulated in cancer, due to underlying genetic mutations, or dysregulated signaling pathways. Cancer drug development relies on proteomic technologies to identify potential biomarkers, mechanisms-of-action, and to identify protein binding hot spots.Areas covered: Brief summaries of proteomic technologies for drug discovery include mass spectrometry, reverse phase protein arrays, chemoproteomics, and fragment based screening. Protein-protein interface mapping is presented as a promising method for peptide therapeutic development. The topic of biosimilar therapeutics is presented as an opportunity to apply proteomic technologies to this new class of cancer drug.Expert opinion: Proteomic technologies are indispensable for drug discovery. A suite of technologies including mass spectrometry, reverse phase protein arrays, and protein-protein interaction mapping provide complimentary information for drug development. These assays have matured into well controlled, robust technologies. Recent regulatory approval of biosimilar therapeutics provides another opportunity to decipher the molecular nuances of their unique mechanisms of action. The ability to identify previously hidden protein hot spots is expanding the gamut of potential drug targets. Proteomic profiling permits lead compound evaluation beyond the one drug, one target paradigm.

biochemical research methods
Abstract 1999: Proteogenomic Characterization of Breast Cancer Sub-Types in Patient Derived Xenografts

Harsha P. Gunawardena,John A. Wrobel,Jonathon O'Brien,Ling Xie,Petra Erdmann-Gilmore,Sherri R. Davies,Shunqiang Li,Song Cao,Michael McLellan,Kelly V. Ruggles,David Fenyo,R. Reid Townsend,Li Ding,Bahjat F. Qaqish,Matthew J. Ellis,Xian Chen

DOI: https://doi.org/10.1158/1538-7445.am2015-1999

IF: 11.2

2015-01-01

Cancer Research

Abstract:Abstract The goal of this talk is to introduce an integrated quantitative proteogenomic approach to comprehensively map proteomic information back to their encoding genes. We seek evidence from mass spectrometry-based large-scale proteomic data of patient populations in conjunction with patient-centric next-generation sequencing data and unbiased sequencing strategies to study breast cancer (BC) subtypes from a genomic context. We have obtained global and phosphoproteomic data with matching next generation sequencing data for 18 patient-derived xenografts (PDXs) representing the major clinical subtypes of BC. Our workflow starts with the creation of several protein sequence databases that serve as a template for mass spectrometry database identifications. These databases include 1) completely annotated reference protein sequences, 2) patient-specific databases that were created using next generation sequencing data, 3) isoform databases that contain all possible splicing combinations, and 4) amino acid sequence database resulting from a six-frame translation of the entire human reference and customized genomes. All mass spectrometry raw data are searched against the databases for obtaining identifications at the peptide level, and assembly of peptides for quantification using taxonomy-based label-free quantitation (LFQ) that can specifically quantify unique human peptide sequences found in PDXs. The peptides are then mapped to the human genome and visualized using a genome browser. Quantitative changes across PDXs are presented at the protein level or at the isoform level via peptide role-up to specific exons and visualized as a quantitative data track. By combining search results from these databases we obtain a comprehensive view of our PDXs. The complementary nature of the databases enable greater proteomic depth, i.e. databases with complete splicing combinations capture proteomic evidence when patient-specific databases fail due to possible erroneous RNA-seq reads. Similarly, 6-frame translated amino acid databases can capture potentially novel coding regions but are unable to detect splicing. Peptide maps are obtained for individual genes or specific protein isoforms covering both knowledge-driven and novel genomic annotation types. We compile peptides carrying variants, splice junctions, fusions, and new coding regions specific to each PDX or in common with a specific BC subtype. Majority of data is mapped back to the genome loci using unmodified peptides via global proteomics while phosphopeptides that contain variants and splicing are also mapped in a similar manner using phosphoproteomic data. We have currently annotated 455 novel proteogenomic hits covering many examples outlined above for genes related to breast cancer and show how these can be specifically identified and in some instances differentially quantified in the PDX models. Citation Format: Harsha P. Gunawardena, John A. Wrobel, Jonathon O'Brien, Ling Xie, Petra Erdmann-Gilmore, Sherri R. Davies, Shunqiang Li, Song Cao, Michael McLellan, Kelly V. Ruggles, David Fenyo, R. Reid Townsend, Li Ding, Bahjat F. Qaqish, Matthew J. Ellis, Xian Chen. Proteogenomic characterization of breast cancer sub-types in patient derived xenografts. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 1999. doi:10.1158/1538-7445.AM2015-1999
Integrated proteomic and phosphoproteomic data-independent acquisition data evaluate the personalized drug responses of primary and metastatic tumors in colorectal cancer

Xumiao Li,Yiming Huang,Kuo Zheng,Guanyu Yu,Qinqin Wang,Lei Gu,Jingquan Li,Hui Wang,Wei Zhang,Yidi Sun,Chen Li

DOI: https://doi.org/10.52601/bpr.2022.210048

2023-04-30

Abstract:Mass spectrometry (MS)-based proteomics and phosphoproteomics are powerful methods to study the biological mechanisms, diagnostic biomarkers, prognostic analysis, and drug therapy of tumors. Data-independent acquisition (DIA) mode is considered to perform better than data-dependent acquisition (DDA) mode in terms of quantitative reproducibility, specificity, accuracy, and identification of low-abundance proteins. Mini patient derived xenograft (MiniPDX) model is an effective model to assess the response to antineoplastic drugs in vivo and is helpful for the precise treatment of cancer patients. Kinases are favorable spots for tumor-targeted drugs, and their functional completion relies on signaling pathways through phosphorylating downstream substrates. Kinase-phosphorylation networks or edge interactions are considered more credible and permanent for characterizing complex diseases. Here, we provide a workflow for personalized drug response assessment in primary and metastatic colorectal cancer (CRC) tumors using DIA proteomic data, DIA phosphoproteomic data, and MiniPDX models. Three kinase inhibitors, afatinib, gefitinib, and regorafenib, are tested pharmacologically. The process mainly includes the following steps: clinical tissue collection, sample preparation, hybrid spectral libraries establishment, MS data acquisition, kinase-substrate network construction, in vivo drug test, and elastic regression modeling. Our protocol gives a more direct data basis for individual drug responses, and will improve the selection of treatment strategies for patients without the druggable mutation.
Kinase inhibitor pulldown assay (KiP) for clinical proteomics

Alexander B. Saltzman,Doug W. Chan,Matthew V. Holt,Junkai Wang,Eric J. Jaehnig,Meenakshi Anurag,Purba Singh,Anna Malovannaya,Beom-Jun Kim,Matthew J. Ellis

DOI: https://doi.org/10.1186/s12014-023-09448-3

2024-01-18

Clinical Proteomics

Abstract:Protein kinases are frequently dysregulated and/or mutated in cancer and represent essential targets for therapy. Accurate quantification is essential. For breast cancer treatment, the identification and quantification of the protein kinase ERBB2 is critical for therapeutic decisions. While immunohistochemistry (IHC) is the current clinical diagnostic approach, it is only semiquantitative. Mass spectrometry-based proteomics offers quantitative assays that, unlike IHC, can be used to accurately evaluate hundreds of kinases simultaneously. The enrichment of less abundant kinase targets for quantification, along with depletion of interfering proteins, improves sensitivity and thus promotes more effective downstream analyses. Multiple kinase inhibitors were therefore deployed as a capture matrix for kinase inhibitor pulldown (KiP) assays designed to profile the human protein kinome as broadly as possible. Optimized assays were initially evaluated in 16 patient derived xenograft models (PDX) where KiP identified multiple differentially expressed and biologically relevant kinases. From these analyses, an optimized single-shot parallel reaction monitoring (PRM) method was developed to improve quantitative fidelity. The PRM KiP approach was then reapplied to low quantities of proteins typical of yields from core needle biopsies of human cancers. The initial prototype targeting 100 kinases recapitulated intrinsic subtyping of PDX models obtained from comprehensive proteomic and transcriptomic profiling. Luminal and HER2 enriched OCT-frozen patient biopsies subsequently analyzed through KiP-PRM also clustered by subtype. Finally, stable isotope labeled peptide standards were developed to define a prototype clinical method. Data are available via ProteomeXchange with identifiers PXD044655 and PXD046169.

biochemical research methods
Wireless Valving for Centrifugal Microfluidic Disc

M. A. Zainal,Y. M. Yunos,R. Abdul Rahim,M. S. Mohamed Ali

DOI: https://doi.org/10.1109/JMEMS.2017.2743212

IF: 2.829

2017-09-06

Journal of Microelectromechanical Systems

Abstract:This paper reports a selective wireless active valve mechanism for a centrifugal microfluidic disc operated using field frequency modulation techniques. The device utilizes a planar inductor-capacitor resonant circuit as a heater to heat up the wax-based valve in a microfluidic disc. Selective radio frequency (RF) wireless heating of the valves was utilized to control the liquid flow in the disc. A vacuum/compression valve and mixing applications using the proposed method are demonstrated in this paper. Experimental characterization shows that valve operation is within ~100 s of activation using an RF power of 1 W that provides a temperature increase up to 42 °C at a speed of 200 rpm. The reported technique offers the advantage of localized valve activation and offers a further advance in the centrifugal microfluidic area by enabling full control of liquid flow. [2017–0040]
Histopathologic and immunophenotypic characterization of patient-derived pediatric malignant hepatocellular tumor xenografts (PDXs).

Kalyani R. Patel,Andres F. Espinoza,Martin Urbicain,Roma H. Patel,Angela Major,Stephen F Sarabia,Dolores Lopez-Terrada,Sanjeev A. Vasudevan,Sarah E. Woodfield

DOI: https://doi.org/10.1016/j.prp.2024.155163

IF: 3.309

2024-02-03

Pathology - Research and Practice

Abstract:Advances in targeted therapies for pediatric hepatocellular tumors have been limited due to a paucity of clinically relevant models. Establishment and validation of intrahepatic patient-derived xenograft (PDX) models would help bridging this gap. The aim of this study is to compare the histomorphologic and immunophenotypic fidelity of patient tumors and their corresponding intrahepatic PDX models. Murine PDX models were established by intrahepatic implantation of patient tumors. Pathology slides from both patients and their corresponding PDX models were reviewed and quantitatively assessed for various histologic components and immunophenotypic markers. Ten PDX models were successfully established from nine patients with pre- (n=3) and post- (n=6) chemotherapy samples; diagnosed of hepatoblastoma (n=8) and hepatocellular neoplasm, not otherwise specified (n=1). Two of nine (22.2%) patients showed ≥75% fetal component; however, the corresponding PDX models did not maintain this fetal differentiation. High grade histology was seen in three patients (33.3%) and overrepresented in six PDX models (60%). Within the subset of three PDXs that were further characterized, significant IHC concordance was seen in all 3 models for CK7, CK19, Ki-67, and p53; and 2 of 3 models for Sox9 and Beta-catenin. GPC-3 and GS showed variable to moderate concordance, while Hepar was the least concordant. Our study shows that in general, the PDX models appear to represent the higher-grade component of the original tumor and show significant concordance for Ki-67, making them appropriate tools for testing new therapies for the most aggressive, therapy-resistant tumors.

pathology
Abstract 5726: Pan-cancer Proteogenomics Expands the Landscape of Therapeutic Targets

Jonathan T. Lei,Sara R. Savage,Xinpei Yi,Bo Wen,Hongwei Zhao,Lauren K. Somes,Paul W. Shafer,Yongchao Dou,Qiang Gao,Valentina Hoyos,Bing Zhang

DOI: https://doi.org/10.1158/1538-7445.am2023-5726

IF: 11.2

2023-01-01

Cancer Research

Abstract:Background: Molecularly targeted therapies are critical for improving cancer treatment. Since proteins are the targets of these therapies and functional effectors of genomic aberrations, proteogenomics data from the Clinical Proteomics Tumor Analysis Consortium (CPTAC) provides an unprecedented opportunity to characterize existing and future therapeutic targets for cancer treatment. Approach: CPTAC proteogenomics data from >1000 cancer patients spanning 10 cancer types was used to evaluate current and potential therapeutic targets curated from four databases. Cell line data from DepMap was further integrated to distinguish causations from associations. Computational pipelines were deployed to identify synthetic lethality for targeting tumor suppressor loss and to prioritize tumor associated antigens as immunotherapy targets. Results: We systematically collected 3050 druggable proteins and classified them into 5 tiers to facilitate different applications such as companion diagnostics, drug repurposing, and new therapy development. Many druggable proteins showed poor mRNA-protein correlation, including secreted proteins and proteins whose abundance was correlated with their interaction partners instead of cognate mRNA, highlighting the necessity of direct proteomic quantification of drug targets. 618 druggable proteins showed both overexpression in tumors compared to normal and significant dependency in CRISPR-Cas9 screens of cell lines of the same lineage. Notably, PAK1, a kinase targeted by investigational drugs, demonstrated both overexpression and dependency in all cancer types. A similar analysis of phosphoproteomics data focusing on known activating sites of druggable proteins further revealed targetable dependencies driven by protein hyperactivation. The phosphosite pS50 on PTPN1, a phosphatase targeted by experimental drugs, was increased in 7 cancer types and PTPN1 demonstrated dependency in related cancer cell lines. Based on tumor proteogenomic data and cell line CRISPR-Cas9 screen data, we identified synthetic lethality for difficult to target tumor suppressor losses, revealing TP53 mutations as a candidate biomarker to select breast cancer patients for CHEK1 inhibition, and endometrial cancer patients for treatment with doxorubicin. We identified 140 proteins whose expression was restricted in normal tissues but abnormal in tumors. Experimental analysis of peptides predicted to have high binding affinity to the most common allotype HLA-A02 for 7 prioritized proteins identified 21 peptides from 5 proteins with both strong binding affinity and immunogenicity which could be further investigated as immunotherapy targets. Conclusion: We generate a comprehensive resource of protein and peptide targets that covers multiple therapeutic modalities. This unique resource will pave the way for repurposing of currently available drugs and developing new drugs for cancer treatment. Citation Format: Jonathan T. Lei, Sara R. Savage, Xinpei Yi, Bo Wen, Hongwei Zhao, Lauren K. Somes, Paul W. Shafer, Yongchao Dou, Qiang Gao, Valentina Hoyos, Bing Zhang. Pan-cancer proteogenomics expands the landscape of therapeutic targets. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 5726.
A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncology

Katrin P. Guillen,Maihi Fujita,Andrew J. Butterfield,Sandra D. Scherer,Matthew H. Bailey,Zhengtao Chu,Yoko S. DeRose,Ling Zhao,Emilio Cortes-Sanchez,Chieh-Hsiang Yang,Jennifer Toner,Guoying Wang,Yi Qiao,Xiaomeng Huang,Jeffery A. Greenland,Jeffery M. Vahrenkamp,David H. Lum,Rachel E. Factor,Edward W. Nelson,Cindy B. Matsen,Jane M. Poretta,Regina Rosenthal,Anna C. Beck,Saundra S. Buys,Christos Vaklavas,John H. Ward,Randy L. Jensen,Kevin B. Jones,Zheqi Li,Steffi Oesterreich,Lacey E. Dobrolecki,Satya S. Pathi,Xing Yi Woo,Kristofer C. Berrett,Mark E. Wadsworth,Jeffrey H. Chuang,Michael T. Lewis,Gabor T. Marth,Jason Gertz,Katherine E. Varley,Bryan E. Welm,Alana L. Welm

DOI: https://doi.org/10.1038/s43018-022-00337-6

IF: 22.7

2022-02-01

Nature Cancer

Abstract:Abstract Models that recapitulate the complexity of human tumors are urgently needed to develop more effective cancer therapies. We report a bank of human patient-derived xenografts (PDXs) and matched organoid cultures from tumors that represent the greatest unmet need: endocrine-resistant, treatment-refractory and metastatic breast cancers. We leverage matched PDXs and PDX-derived organoids (PDxO) for drug screening that is feasible and cost-effective with in vivo validation. Moreover, we demonstrate the feasibility of using these models for precision oncology in real time with clinical care in a case of triple-negative breast cancer (TNBC) with early metastatic recurrence. Our results uncovered a Food and Drug Administration (FDA)-approved drug with high efficacy against the models. Treatment with this therapy resulted in a complete response for the individual and a progression-free survival (PFS) period more than three times longer than their previous therapies. This work provides valuable methods and resources for functional precision medicine and drug development for human breast cancer.

English Else
Proteogenomic Landscape of Breast Cancer Tumorigenesis and Targeted Therapy

Karsten Krug,Eric J. Jaehnig,Shankha Satpathy,Lili Blumenberg,Alla Karpova,Meenakshi Anurag,George Miles,Philipp Mertins,Yifat Geffen,Lauren C. Tang,David I. Heiman,Song Cao,Yosef E. Maruvka,Jonathan T. Lei,Chen Huang,Ramani B. Kothadia,Antonio Colaprico,Chet Birger,Jarey Wang,Yongchao Dou,Bo Wen,Zhiao Shi,Yuxing Liao,Maciej Wiznerowicz,Matthew A. Wyczalkowski,Xi Steven Chen,Jacob J. Kennedy,Amanda G. Paulovich,Mathangi Thiagarajan,Christopher R. Kinsinger,Tara Hiltke,Emily S. Boja,Mehdi Mesri,Ana I. Robles,Henry Rodriguez,Thomas F. Westbrook,Li Ding,Gad Getz,Karl R. Clauser,David Fenyö,Kelly V. Ruggles,Bing Zhang,D.R. Mani,Steven A. Carr,Matthew J. Ellis,Michael A. Gillette,Clinical Proteomic Tumor Analysis Consortium,Shayan C. Avanessian,Shuang Cai,Daniel Chan,Xian Chen,Nathan J. Edwards,Andrew N. Hoofnagle,M. Harry Kane,Karen A. Ketchum,Eric Kuhn,Douglas A. Levine,Shunqiang Li,Daniel C. Liebler,Tao Liu,Jingqin Luo,Subha Madhavan,Chris Maher,Jason E. McDermott,Peter B. McGarvey,Mauricio Oberti,Akhilesh Pandey,Samuel H. Payne,David F. Ransohoff,Robert C. Rivers,Karin D. Rodland,Paul Rudnick,Melinda E. Sanders,Kenna M. Shaw,Ie-Ming Shih,Robbert J.C. Slebos,Richard D. Smith,Michael Snyder,Stephen E. Stein,David L. Tabb,Ratna R. Thangudu,Stefani Thomas,Yue Wang,Forest M. White,Jeffrey R. Whiteaker,Gordon A. Whiteley,Hui Zhang,Zhen Zhang,Yingming Zhao,Heng Zhu,Lisa J. Zimmerman

DOI: https://doi.org/10.1016/j.cell.2020.10.036

IF: 64.5

2020-11-01

Cell

Abstract:The integration of mass spectrometry-based proteomics with next-generation DNA and RNA sequencing profiles tumors more comprehensively. Here this "proteogenomics" approach was applied to 122 treatment-naive primary breast cancers accrued to preserve post-translational modifications, including protein phosphorylation and acetylation. Proteogenomics challenged standard breast cancer diagnoses, provided detailed analysis of the ERBB2 amplicon, defined tumor subsets that could benefit from immune checkpoint therapy, and allowed more accurate assessment of Rb status for prediction of CDK4/6 inhibitor responsiveness. Phosphoproteomics profiles uncovered novel associations between tumor suppressor loss and targetable kinases. Acetylproteome analysis highlighted acetylation on key nuclear proteins involved in the DNA damage response and revealed cross-talk between cytoplasmic and mitochondrial acetylation and metabolism. Our results underscore the potential of proteogenomics for clinical investigation of breast cancer through more accurate annotation of targetable pathways and biological features of this remarkably heterogeneous malignancy.

cell biology,biochemistry & molecular biology
Addressing the Challenges of High‐Throughput Cancer Tissue Proteomics for Clinical Application: ProCan

Brett Tully,Rosemary L. Balleine,Peter G. Hains,Qing Zhong,Roger R. Reddel,Phillip J. Robinson

DOI: https://doi.org/10.1002/pmic.201900109

2019-09-24

PROTEOMICS

Abstract:The cancer tissue proteome has enormous potential as a source of novel predictive biomarkers in oncology. Progress in development of mass spectrometry (MS)‐based tissue proteomics now presents an opportunity to exploit this by applying the strategies of comprehensive molecular profiling and big‐data analytics that have been refined in other fields of 'omics research. ProCan® is a program aiming to generate high‐quality tissue proteomic data across a broad spectrum of cancer types. It is based on data‐independent acquisition (DIA)‐MS proteomic analysis of annotated tissue samples sourced through collaboration with expert clinical and cancer research groups. The practical requirements of a high‐throughput translational research program have shaped the approach that ProCan is taking to address challenges in study design, sample preparation, raw data acquisition and data analysis. The ultimate goal is to establish a large proteomics knowledge‐base that, in combination with other cancer 'omics data, will accelerate cancer research.This article is protected by copyright. All rights reserved

biochemistry & molecular biology,biochemical research methods
Abstract GS2-05: Microscaled Proteogenomic Methods for Precision Oncology

Shankha Satpathy,Eric Jaehnig,Krug Karsten,Beom-Jun Kim,Alexander Saltzman,Doug Chan,Kimberly Holloway,Meenakshi Anurag,Chen Huang,Purba Singh,Ari Gao,Noel Namai,Yongchao Dou,Bo Wen,Suhas Vasaikar,David Mutch,Mark Watson,Cynthia Ma,Foluso Ademuyiwa,Mothaffar Rimawi,Jeremy Hoog,Samuel Jacobs,Anna Malovannaya,Terry Hyslop,D.R Mani,Charles Perou,George Miles,Bing Zhang,Michael Gillette,Steven Carr,Matthew Ellis

DOI: https://doi.org/10.1158/1538-7445.sabcs19-gs2-05

IF: 11.2

2020-01-01

Cancer Research

Abstract:Abstract Cancer proteogenomics combines genomics, transcriptomics and mass spectrometry-based proteomics to gain insights into cancer biology and treatment responsiveness. While proteogenomics analyses have already shown great potential to deepen our understanding of cancer tissue complexity and signaling, how a patient’s tumor changes upon treatment has largely been the province of genomics. This is due to technical difficulties associated with doing proteogenomic analysis on clinic-derived core-needle biopsies. To address this critical need, we have developed a “microscaled” proteogenomics approach for tumor-rich OCT-embedded core needle biopsies. Tissue-sparing specimen processing (“Biopsy Trifecta EXTraction”, BioTExt) and microscaled proteomics (MiProt) methodologies allowed generation of deep-scale proteogenomics datasets, with copy number and transcript information for >20,000 genes and mass spectrometry-based identification and quantification of nearly all expressed proteins in a tumor (>10,000 proteins) and more than >20,000 phosphosites starting with just 25 micrograms of protein per sample. In order to understand the capabilities and limitations our our approach relative to more conventional deepscale proteomics requiring >10X more starting material, we compared preclinical patient derived xenograft (PDX) models at conventional scale with data obtained by core-needle biopsy of the same tissues. Comparable depth and biological insights were obtained from the cores relative to surgically resected tumors. As a proof-of-concept for implementation in clinical trials, we applied microscaled proteogenomic methods to a small-scale clinical study where biopsies were accrued from patients with ERBB2+ locally advanced breast cancer before and 48 to 72 hours after the first dose of neoadjuvant Trastuzumab-based chemotherapy. Multi-omics comparisons were conducted between samples associated with residual disease versus samples associated with complete pathological response. Integrative, microscaled proteogenomic analyses efficiently diagnosed the molecular bases of diverse candidate treatment resistance mechanisms including: 1) absence of ERBB2 amplification (false-ERBB2+); 2) insufficient ERBB2 activity for therapeutic sensitivity despite ERBB2 amplification (pseudo-ERBB2+); 3) resistance features in true-ERBB2+ cases including androgen receptor signaling, mucin expression and an inactive immune microenvironment; 4) lack of acute phospho-ERBB2 down-regulation in non-pCR cases. In summary, we have developed a robust proteogenomics pipeline well suited for large-scale cancer clinical studies to identify potential resistance mechanism in patients. We conclude that microscaled cancer proteogenomics could improve diagnostic precision in the clinical setting. Citation Format: Shankha Satpathy, Eric Jaehnig, Krug Karsten, Beom-Jun Kim, Alexander Saltzman, Doug Chan, Kimberly Holloway, Meenakshi Anurag, Chen Huang, Purba Singh, Ari Gao, Noel Namai, Yongchao Dou, Bo Wen, Suhas Vasaikar, David Mutch, Mark Watson, Cynthia Ma, Foluso Ademuyiwa, Mothaffar Rimawi, Jeremy Hoog, Samuel Jacobs, Anna Malovannaya, Terry Hyslop, D.R Mani, Charles Perou, George Miles, Bing Zhang, Michael Gillette, Steven Carr, Matthew Ellis. Microscaled proteogenomic methods for precision oncology [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr GS2-05.

The conversion stage of skin carcinogenesis.

Integrative Pharmacogenomics Analysis of Patient-Derived Xenografts

Proteomics and personalized patient-derived xenograft models identify treatment opportunities for a progressive malignancy within a clinically actionable timeframe and change care

Proteogenomic Integration Reveals Therapeutic Targets in Breast Cancer Xenografts.

Proteomics‐based interrogation of the kinome and its implications for precision oncology

Personalized Cancer Therapy Using a Patient-Derived Tumor Tissue Xenograft Model: a Translational Field Worthy of Exploring Further?

Proteomic insights into paediatric cancer: Unravelling molecular signatures and therapeutic opportunities

A Targeted Quantitative Proteomics Strategy for Global Kinome Profiling of Cancer Cells and Tissues

Abstract 937: Prioritizing treatment targets for an adolescent with metastatic processive malignancy using proteomics and personalized xenograft models within an actionable timeframe

Abstract 6915: Integrated proteogenomic analysis for the NCI patient-derived cancer model repository

Proteomics for cancer drug design

Abstract 1999: Proteogenomic Characterization of Breast Cancer Sub-Types in Patient Derived Xenografts

Integrated proteomic and phosphoproteomic data-independent acquisition data evaluate the personalized drug responses of primary and metastatic tumors in colorectal cancer

Kinase inhibitor pulldown assay (KiP) for clinical proteomics

Wireless Valving for Centrifugal Microfluidic Disc

Histopathologic and immunophenotypic characterization of patient-derived pediatric malignant hepatocellular tumor xenografts (PDXs).

Abstract 5726: Pan-cancer Proteogenomics Expands the Landscape of Therapeutic Targets

A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncology

Proteogenomic Landscape of Breast Cancer Tumorigenesis and Targeted Therapy

Addressing the Challenges of High‐Throughput Cancer Tissue Proteomics for Clinical Application: ProCan

Abstract GS2-05: Microscaled Proteogenomic Methods for Precision Oncology